Jazz Pharmaceuticals PLC

11 nov. 2026, 21:31 UTC

Jazz Pharmaceuticals PLC shares advanced modestly higher in after-market trading, recovering from an initial dip to reach a peak by 16:20 ET.

10 nov. 2026, 20:52 UTC

Jazz Pharmaceuticals PLC is trading higher, supported by broader market strength and three consecutive daily closes, despite a slight pullback from its peak return.

9 nov. 2026, 21:04 UTC

Jazz Pharmaceuticals PLC shares are advancing amid a broader market trend of higher daily closes since Friday, despite a downward shift in today's action.

6 nov. 2026, 22:41 UTC

Jazz Pharmaceuticals PLC shares are advancing in after-market trading, buoyed by strong U.S. economic data, including rising non-farm payrolls and a lower unemployment rate.

5 nov. 2026, 21:04 UTC

Jazz Pharmaceuticals PLC shares fell amid broader market weakness, driven by economic data and uncertainty following the Bank of England's interest rate hike to 4%.

4 nov. 2026, 21:03 UTC

Jazz Pharmaceuticals PLC is trading higher, continuing a steady advance since Tuesday's close and maintaining a position above its 20-day moving average.

3 nov. 2026, 21:03 UTC

Analysts upgraded Jazz Pharmaceuticals PLC, with Barclays raising its price target to $275 and JP Morgan increasing theirs to $310, following strong quarterly earnings.

2 nov. 2026, 23:16 UTC

Jazz Pharmaceuticals reports record Q3 revenues of $1.2 billion and raises full-year guidance to $4.775 billion to $4.850 billion despite a net loss of $483.4 million.

30 oct. 2026, 20:04 UTC

Jazz Pharmaceuticals PLC shares are advancing amid a broader market context, breaking from a recent trend of higher daily closes since Thursday's close.

29 oct. 2026, 20:06 UTC

Jazz Pharmaceuticals PLC shares advanced, reflecting a notable increase since Wednesday's close, despite pulling back slightly from a mid-morning peak.

28 oct. 2026, 19:16 UTC

JPMorgan analyst Jessica Fye raised the price target on Jazz Pharmaceuticals to $300 from $276 while maintaining an Overweight rating.

27 oct. 2026, 23:06 UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading following a 16% year-over-year revenue increase for Q2, driven by $471.2 million in Xywav sales.

26 oct. 2026, 21:03 UTC

Jazz Pharmaceuticals PLC reported a pre-tax charge of approximately $755 million from its Actio Biosciences acquisition, impacting earnings per share by around $11.00 for Q3 2026.

23 oct. 2026, 23:56 UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading, rebounding sharply after an initial decline, reflecting a cumulative gain since Friday's close.

22 oct. 2026, 20:13 UTC

Jazz Pharmaceuticals PLC shares advanced in after-market trading, reflecting a notable uptick since Thursday's close while remaining below its 20-day moving average.

21 oct. 2026, 19:26 UTC

Morgan Stanley analyst Jeffrey Hung lowered the price target on Jazz Pharmaceuticals to $314.00 from $322.00 while maintaining an Overweight rating.

20 oct. 2026, 20:08 UTC

Jazz Pharmaceuticals PLC shares advanced, reaching a peak early in the session before pulling back slightly, while trading below its 20-day moving average.

19 oct. 2026, 19:16 UTC

Jazz Pharmaceuticals PLC shares are declining sharply, currently trading significantly below their 20-day moving average and near the lower end of their one-month range.

16 oct. 2026, 21:01 UTC

Jazz Pharmaceuticals PLC declined in after-market trading, continuing a trend of unusual weakness since Friday's close and remaining below its 20-day moving average.

15 oct. 2026, 20:07 UTC

Jazz Pharmaceuticals PLC shares are advancing, continuing a positive trend since Wednesday's close, despite earlier pulling back from a session high.

14 oct. 2026, 19:36 UTC

Jazz Pharmaceuticals PLC shares are advancing, having pulled back from an earlier peak, while remaining below their 20-day moving average.

13 oct. 2026, 20:02 UTC

Jazz Pharmaceuticals PLC shares fell lower, marking a departure from recent higher daily closes amid shifts in broader market momentum.

12 oct. 2026, 19:16 UTC

Jazz Pharmaceuticals PLC shares fell modestly, continuing a trend of three consecutive sessions with lower closes, despite a brief recovery earlier in the day.

9 oct. 2026, 23:45 UTC

Jazz Pharmaceuticals PLC shares are trading slightly lower in after-market hours, marking three consecutive daily declines and remaining significantly below their 20-day moving average.

8 oct. 2026, 20:02 UTC

RBC Capital analyst Leonid Timashev lowered Jazz Pharmaceuticals' price target to $296.00 from $299.00 while keeping an Outperform rating.

7 oct. 2026, 21:21 UTC

In after-market trading, Jazz Pharmaceuticals PLC saw a notable increase, reaching a peak return after gaining higher since Wednesday's close.

6 oct. 2026, 20:07 UTC

Jazz Pharmaceuticals PLC shares declined after Director Bruce C. Cozadd sold 6k shares, with the stock remaining significantly below its 20-day moving average.

1 oct. 2026, 19:25 UTC

Jazz Pharmaceuticals PLC is trading higher, reflecting positive movement since Wednesday's close, despite retracing from an earlier peak and remaining below its 20-day moving average.

30 sept. 2026, 20:07 UTC

Jazz Pharmaceuticals PLC shares fell as the broader market showed weakness, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

29 sept. 2026, 20:02 UTC

Jazz Pharmaceuticals PLC shares fell sharply, reaching their lowest cumulative return since Monday and trading well below the 20-day moving average.